<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24625" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Macrolides</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Parth H.</given-names>
          </name>
          <aff>LECOM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hashmi</surname>
            <given-names>Muhammad F.</given-names>
          </name>
          <aff>National Health Service</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Parth Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Hashmi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>16</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24625.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Macrolides are a class of drugs used to manage and treat various bacterial infections. Azithromycin, clarithromycin, and erythromycin are commonly used to treat infections like pneumonia, sinusitis, pharyngitis, and tonsillitis. They are also used in uncomplicated skin infections and otitis media in pediatric patients. Clarithromycin is used to treat Helicobacter pylori infections in standard triple therapy protocol regardless of clarithromycin resistance status. Macrolides are also commonly used to treat sexually transmitted infections such as gonococcal and chlamydial infections. This activity reviews the mechanism of action, indications, contraindications, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) related to macrolides.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of the macrolide class of antibiotics.</p></list-item><list-item><p>Describe the potential adverse effects of the macrolide class of antibiotics.</p></list-item><list-item><p>Review the appropriate monitoring necessary for patients on agents in the macrolide class of antibiotics.</p></list-item><list-item><p>Describe interprofessional team strategies for improving the proper administration and management of macrolide antibiotics.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24625&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24625">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24625.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Macrolides are naturally occurring compounds comprised of a lactone ring with deoxy sugars attached. Certain macrolides have antibiotic or antifungal properties and&#x000a0;are used in pharmaceutical antimicrobial therapy. The first macrolide used in this manner was erythromycin in 1952; it was often used for infections in patients who were allergic to penicillin or whose infections were penicillin-resistant.<xref ref-type="bibr" rid="article-24625.r1">[1]</xref></p>
        <p>The FDA has approved the use of macrolide antibiotic agents for a wide variety of bacterial infections. In particular, azithromycin, clarithromycin, and erythromycin are commonly used to treat infections like pneumonia, sinusitis, pharyngitis, and tonsillitis. Also, the FDA has approved its use in uncomplicated skin infections and otitis media in pediatric patients. Moreover, clarithromycin is used to treat <italic toggle="yes">Helicobacter pylori</italic> infections in standard triple therapy protocol regardless of clarithromycin resistance status. Macrolides are also commonly used to treat sexually transmitted infections such as gonococcal and chlamydial infections. The majority of macrolide use, like other antibiotics, is dictated by the susceptibility and resistance status of the targetted organism.<xref ref-type="bibr" rid="article-24625.r2">[2]</xref><xref ref-type="bibr" rid="article-24625.r3">[3]</xref><xref ref-type="bibr" rid="article-24625.r4">[4]</xref>&#x000a0;Macrolides have also been one of the primary drugs used to treat atypical pneumonia, usually caused by organisms like <italic toggle="yes">Mycoplasma pneumoniae</italic>, <italic toggle="yes">Legionella</italic>, and <italic toggle="yes">Chlamydia pneumoniae</italic>.<xref ref-type="bibr" rid="article-24625.r5">[5]</xref></p>
        <p>In recent studies, macrolide maintenance therapy has been shown to improve quality of life and spirometry findings in adults and children with non-cystic fibrosis bronchiectasis. Further, these agents have been shown to reduce the number of bronchiectasis exacerbations. However, these studies&#x000a0;revealed no reduction in hospital admissions pertaining to exacerbations.<xref ref-type="bibr" rid="article-24625.r6">[6]</xref></p>
        <p>Macrolides remain an integral part of treatment regimens for COPD exacerbations. The use of these drugs in COPD is because of their anti-inflammatory and immunomodulating characteristics.<xref ref-type="bibr" rid="article-24625.r7">[7]</xref></p>
      </sec>
      <sec id="article-24625.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Macrolies inhibit bacterial protein synthesis. The mechanism of action of macrolides revolves around their ability to bind the bacterial 50S ribosomal subunit causing the cessation of bacterial protein synthesis. Once it binds, the drug prevents the translation of mRNA, specifically the growing peptide chain, by preventing the enzyme peptidyltransferase from adding the&#x000a0;subsequent amino acid&#x000a0;attached to the tRNA. Since the bacterial ribosomal structure is highly conserved across most, if not all, bacterial species, it is considered broad-spectrum.<xref ref-type="bibr" rid="article-24625.r8">[8]</xref>&#x000a0;Macrolides are bacteriostatic agents as they only inhibit&#x000a0;protein synthesis, although, at high doses,&#x000a0;they can be bactericidal.</p>
        <p>The anti-inflammatory and immunomodulatory effects of macrolides, particularly azithromycin, are attributed to interactions with phospholipids as well as transcription factors AP-1, NF-kappaB, and other inflammatory cytokines. Later changes seen in macrophages that interact with macrolides include inhibition of cell function, cellular transport, and surface receptor expression regulation. All of these culminate in the immunomodulatory effects of macrolides in the body.<xref ref-type="bibr" rid="article-24625.r2">[2]</xref></p>
        <p>Due to the overprescription of antibiotics, there has been tremendous growth in resistance to many mainstay therapies. Macrolides are no exception to this situation, and many organisms are excessively resistant to them. The primary&#x000a0;cause of macrolide bacterial resistance&#x000a0;is post-transcriptional methylation of the bacterial 23S&#x000a0;ribosomal RNA. This acquired resistance can&#x000a0;occur via two mechanisms: it can be plasmid-mediated&#x000a0;chromosomal.<xref ref-type="bibr" rid="article-24625.r9">[9]</xref> Studies show a solid link to genetic mutations in bacteria and the ability to spread these genes via transposable elements. The gene in question allows bacteria to be resistant to macrolides, lincosamides, and streptogramin groups of antibiotics at once.<xref ref-type="bibr" rid="article-24625.r10">[10]</xref></p>
      </sec>
      <sec id="article-24625.s4" sec-type="Administration">
        <title>Administration</title>
        <p>The formulation of the drug requires discussion with the administering provider. The factors that one needs to consider are strength, dosage, route, clinical goals of treatment, etc. Macrolides come in various forms for administration, depending on the desired medication and the reason for their use. Most commonly used are oral formulations in tablet form, but they also come&#x000a0;as topical creams, intravenous formulations, as well as ophthalmic preparations.<xref ref-type="bibr" rid="article-24625.r4">[4]</xref></p>
        <p>The following list includes the most common macrolides and their most common formulations; however, other formulations and dosages do exist:</p>
        <list list-type="bullet">
          <list-item>
            <p>Erythromycin
<list list-type="bullet"><list-item><p>Oral tablets: 250 mg / 500 mg</p></list-item><list-item><p>Ophthalmic ointment: 0.5%</p></list-item><list-item><p>Topical gel or solution: 2%</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Clarithromycin
<list list-type="bullet"><list-item><p>Oral tablets: 125 mg / 250 mg / 500 mg (extended-release) &#x02013; oral tablets</p></list-item><list-item><p>Powder for reconstitution: 125 mg/5mL (oral suspension)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Azithromycin
<list list-type="bullet"><list-item><p>Oral tablets: 100 mg / 250mg / 500mg / 600mg &#x02013; oral tablets</p></list-item><list-item><p>Powder for injection: 500 mg</p></list-item><list-item><p>Powder for reconstitution: 100 mg/5 mL / 200 mg/5 mL, and 1 g dose packet (oral suspension)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Fidaxomicin
<list list-type="bullet"><list-item><p>Oreal tablets: 200 mg</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24625.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Like any other antibiotic, macrolides carry a certain level of risk&#x000a0;from typical adverse effects like nausea, vomiting, abdominal pain, and diarrhea. Abdominal symptoms are largely the result of macrolides being motilin agonists causing an increased risk&#x000a0;of gastrointestinal upset and side effects.<xref ref-type="bibr" rid="article-24625.r11">[11]</xref>&#x000a0;Besides, the enteric gut flora is susceptible to the effects of macrolides; therefore, it can cause an imbalance between commensal bacteria native to the human gut and pathogenic bacteria to be kept in check.</p>
        <p>Another common adverse effect of macrolide use is their propensity to prolong the QT and QTc interval in the cardiac cycle. Erythromycin has the highest tendency, and azithromycin has the lowest. The increase in the intervals puts patients at risk of cardiac arrhythmias like Torsades de pointes, ventricular tachycardia, and ventricular fibrillation. The most common arrhythmia arising from the use of macrolides would be Torsades de Pointes.<xref ref-type="bibr" rid="article-24625.r12">[12]</xref>&#x000a0;&#x000a0;</p>
        <p>Recent studies on macrolides have also shown that the use of these drugs correlates with sensorineural hearing loss. While the majority of cases were reversible with cessation of the drug, few cases resulted in irreversible sensorineural hearing loss. Studies have shown that hearing loss can occur both at standard doses and increased doses.<xref ref-type="bibr" rid="article-24625.r13">[13]</xref>&#x000a0;</p>
        <p>Serious side effects like Stevens-Johnsons syndrome and toxic epidermal necrolysis, although rare, are a possibility and should be kept in mind while prescribing these drugs.<xref ref-type="bibr" rid="article-24625.r14">[14]</xref> &#x000a0;</p>
        <p>Erythromycin also has correlations with hepatotoxicity in pregnant women. Moreover, these drugs increase the chances of pyloric stenosis in newborns.<xref ref-type="bibr" rid="article-24625.r4">[4]</xref></p>
      </sec>
      <sec id="article-24625.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Overall, macrolides are a safe group of antibiotics to take, but relative contraindications exist due to the adverse effects profile&#x000a0;and their&#x000a0;ability to interact with other drugs. Patients with prolonged QT intervals on electrocardiograms should avoid macrolides due to their arrhythmogenic characteristics. Further, patients with congenital conditions like long QT syndrome type 2 should also avoid these drugs. Patients taking Class Ia and Class III antiarrhythmic agents should also avoid macrolides as both of these drug classes cause an increase in QT interval and induce arrhythmias.<xref ref-type="bibr" rid="article-24625.r15">[15]</xref></p>
        <p>Macrolides can exhibit adverse interactions with some commonly used drugs.&#x000a0;Carbamazepine, cyclosporin, terfenadine, astemizole, and theophylline interactions are the most frequently encountered with macrolide antibiotics. As a CYP3A4 inhibitor, erythromycin is more prone to drug-drug interactions mediated by CYP3A4; clarithromycin is much less apt to interact in this manner azithromycin does not participate in these interactions.<xref ref-type="bibr" rid="article-24625.r16">[16]</xref></p>
        <p>Pregnant women should also try to avoid using macrolides, specifically erythromycin, due to possible side effects&#x000a0;affecting the mother or the newborn.<xref ref-type="bibr" rid="article-24625.r17">[17]</xref></p>
        <p>Due to the increasing rate of antibiotic resistance, macrolides should be prescribed with caution, and the prescriber should take into account the local resistance status of common pathogens.</p>
      </sec>
      <sec id="article-24625.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>When prescribing macrolides, the prescriber should consider the variety of gastrointestinal side effects and cardiac effects that the patient could encounter with macrolide use. In most patients, gastrointestinal side effects will be the most common, and the team should be ready to take proper measures to counter these effects. Due to the risk of QT prolongation, careful monitoring of&#x000a0;patients with cardiac conditions as well as those taking antiarrhythmics or drugs known to cause interaction should be carried out. Prescribers should also be aware of possible dermatologic side effects and thus should&#x000a0;counsel patients on the side effects. Concerning possible side effects in pregnant women and newborns, patients require counsel on the adverse effects of these drugs in pregnancy,&#x000a0;including the probable adverse&#x000a0;impact on the newborn when prescribing these drugs.</p>
      </sec>
      <sec id="article-24625.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Due to the severity of the cardiac side effects, monitoring the QT interval on ECG should be done in high-risk patients to avoid the induction of deadly arrhythmias like Torsades de Pointes. Patients at high risk should have electrolytes checked before administering the medications, specifically calcium, potassium, and magnesium.<xref ref-type="bibr" rid="article-24625.r4">[4]</xref>&#x000a0;Cessation of the drug is necessary if serious side effects arise in a patient. If possible, another antibiotic should be used over macrolides in these high-risk patients to avoid the chance of inducing arrhythmias.</p>
      </sec>
      <sec id="article-24625.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Although&#x000a0;macrolides are a very safe class of antibiotics, proper healthcare administration by the entire interprofessional team should be done to minimize adverse events. All members of the interprofessional healthcare team should monitor patients for the common side effects as well as the uncommon ones. All members need education regarding common gastrointestinal side effects and the serious cardiac effects this drug has. Every healthcare team member shares the responsibility of providing top-notch care to their patients and should always be on the lookout for potential side effects.</p>
        <p>When deciding to initiate macrolide therapy, the clinician (MD, DO, NP, or PA) would do well to include a pharmaceutical consult, which would consist of verifying the appropriateness of the agent chosen, verification of proper dosing, and checking for drug-drug interactions. Pharmacists can also assist the patient by answering their questions, warning of signs of adverse events, reinforcing prescriber directions, and reporting any concerns they may have to the clinician. Nursing can monitor and answer patient questions about their therapy and report to the prescriber on treatment progress or lack thereof or the presence of adverse effects. All&#x000a0;interprofessional team members should know the&#x000a0;most common uses of the macrolide class of antibiotics and exercise collaborative efforts to ensure optimal patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-24625.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24625&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24625">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24625/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24625">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24625.s11">
        <title>References</title>
        <ref id="article-24625.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klein</surname>
                <given-names>JO</given-names>
              </name>
            </person-group>
            <article-title>History of macrolide use in pediatrics.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>427</fpage>
            <page-range>427-31</page-range>
            <pub-id pub-id-type="pmid">9109154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24625.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parnham</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Erakovic Haber</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Giamarellos-Bourboulis</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Perletti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Verleden</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Vos</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Azithromycin: mechanisms of action and their relevance for clinical applications.</article-title>
            <source>Pharmacol Ther</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>143</volume>
            <issue>2</issue>
            <fpage>225</fpage>
            <page-range>225-45</page-range>
            <pub-id pub-id-type="pmid">24631273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24625.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yeo</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Shiu</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Liou</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CY</given-names>
              </name>
              <collab>Taiwan Gastrointestinal Disease and Helicobacter Consortium</collab>
            </person-group>
            <article-title>First-line <italic>Helicobacter pylori</italic> eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis.</article-title>
            <source>Gut</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <page-range>20-27</page-range>
            <pub-id pub-id-type="pmid">27670375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24625.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Farzam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nessel</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Quick</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <chapter-title>Erythromycin</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>2</day>
            <pub-id pub-id-type="pmid">30335282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24625.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cunha</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>The atypical pneumonias: clinical diagnosis and importance.</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2006</year>
            <month>May</month>
            <volume>12 Suppl 3</volume>
            <fpage>12</fpage>
            <page-range>12-24</page-range>
            <pub-id pub-id-type="pmid">16669925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24625.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gao</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>ZY</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Macrolide therapy in adults and children with non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis.</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>e90047</fpage>
            <pub-id pub-id-type="pmid">24603554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24625.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qiu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Macrolides: a promising pharmacologic therapy for chronic obstructive pulmonary disease.</article-title>
            <source>Ther Adv Respir Dis</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>147</fpage>
            <page-range>147-155</page-range>
            <pub-id pub-id-type="pmid">28030992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24625.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>V&#x000e1;zquez-Laslop</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mankin</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>How Macrolide Antibiotics Work.</article-title>
            <source>Trends Biochem Sci</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>9</issue>
            <fpage>668</fpage>
            <page-range>668-684</page-range>
            <pub-id pub-id-type="pmid">30054232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24625.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munita</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Arias</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of Antibiotic Resistance.</article-title>
            <source>Microbiol Spectr</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">27227291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24625.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marosevic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kaevska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jaglic</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Resistance to the tetracyclines and macrolide-lincosamide-streptogramin group of antibiotics and its genetic linkage - a review.</article-title>
            <source>Ann Agric Environ Med</source>
            <year>2017</year>
            <month>Jun</month>
            <day>12</day>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>338</fpage>
            <page-range>338-344</page-range>
            <pub-id pub-id-type="pmid">28664720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24625.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carter</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Woodhead</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Milavetz</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal side effects with erythromycin preparations.</article-title>
            <source>Drug Intell Clin Pharm</source>
            <year>1987</year>
            <month>Sep</month>
            <volume>21</volume>
            <issue>9</issue>
            <fpage>734</fpage>
            <page-range>734-8</page-range>
            <pub-id pub-id-type="pmid">3498618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24625.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albert</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Schuller</surname>
                <given-names>JL</given-names>
              </name>
              <collab>COPD Clinical Research Network</collab>
            </person-group>
            <article-title>Macrolide antibiotics and the risk of cardiac arrhythmias.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2014</year>
            <month>May</month>
            <day>15</day>
            <volume>189</volume>
            <issue>10</issue>
            <fpage>1173</fpage>
            <page-range>1173-80</page-range>
            <pub-id pub-id-type="pmid">24707986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24625.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ikeda</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Prince</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JX</given-names>
              </name>
              <name>
                <surname>Lieu</surname>
                <given-names>JEC</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Macrolide-associated sensorineural hearing loss: A systematic review.</article-title>
            <source>Laryngoscope</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>128</volume>
            <issue>1</issue>
            <fpage>228</fpage>
            <page-range>228-236</page-range>
            <pub-id pub-id-type="pmid">28771738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24625.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Stevens-Johnson syndrome after erythromycin therapy while deployed at sea.</article-title>
            <source>Mil Med</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>165</volume>
            <issue>8</issue>
            <fpage>636</fpage>
            <page-range>636-7</page-range>
            <pub-id pub-id-type="pmid">10957862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24625.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berger</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>van Weteringen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>van der Sijs</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hunfeld</surname>
                <given-names>NGM</given-names>
              </name>
              <name>
                <surname>Bunge</surname>
                <given-names>JJH</given-names>
              </name>
              <name>
                <surname>de Groot</surname>
                <given-names>NMS</given-names>
              </name>
              <name>
                <surname>van den Bemt</surname>
                <given-names>PMLA</given-names>
              </name>
              <name>
                <surname>van Gelder</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Dynamics of the QTc interval over a 24-h dose interval after start of intravenous ciprofloxacin or low-dose erythromycin administration in ICU patients.</article-title>
            <source>Pharmacol Res Perspect</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>e00865</fpage>
            <pub-id pub-id-type="pmid">34697899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24625.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von Rosensteil</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Adam</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Macrolide antibacterials. Drug interactions of clinical significance.</article-title>
            <source>Drug Saf</source>
            <year>1995</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>105</fpage>
            <page-range>105-22</page-range>
            <pub-id pub-id-type="pmid">7576262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24625.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andersson</surname>
                <given-names>NW</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study.</article-title>
            <source>BMJ</source>
            <year>2021</year>
            <month>Feb</month>
            <day>10</day>
            <volume>372</volume>
            <fpage>n107</fpage>
            <pub-id pub-id-type="pmid">33568349</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
